background
pneumonia
common
caus
death
children
worldwid
account
death
children
year
age
review
summaris
evid
empir
antibiot
treatment
communityacquir
pneumonia
neonat
children
put
emphasi
public
sinc
releas
previou
evid
summari
report
publish
method
systemat
search
systemat
review
metaanalys
antibiot
therapi
communityacquir
pneumonia
conduct
januari
novemb
result
optim
dose
recommend
amoxicillin
remain
unclear
limit
pharmacolog
clinic
evid
limit
evid
surveil
indic
whether
amoxicillin
broader
spectrum
antibiot
eg
thirdgener
cephalosporin
use
commonli
paediatr
cap
differ
region
data
lack
clinic
efficaci
context
pneumococc
staphylococc
mycoplasma
diseas
rel
contribut
vari
firstlin
stepdown
option
select
resist
conclus
pragmat
trial
requir
optimis
manag
hospitalis
children
sever
sever
pneumonia
review
summaris
uptod
evid
empir
antibiot
treatment
communityacquir
pneumonia
cap
neonat
children
updat
special
emphasi
place
public
sinc
releas
previou
report
revis
classif
treatment
pneumonia
children
health
facil
evid
summari
guidelin
recent
major
revis
guidanc
review
summaris
recent
literatur
discuss
emerg
challeng
cap
refer
pneumonia
acquir
commun
pneumonia
account
death
children
year
age
singl
largest
infecti
caus
death
children
worldwid
hivuninfect
children
pneumococc
infect
respons
around
death
age
group
nearli
children
age
year
hospitalis
year
cap
howev
children
symptom
pneumonia
taken
outsid
home
care
pneumonia
affect
children
famili
everywher
preval
south
asia
subsaharan
africa
sign
progress
countri
includ
countdown
group
number
death
pneumonia
children
declin
nonetheless
cap
remain
issu
profound
econom
social
import
children
commun
worldwid
aetiolog
studi
cap
children
complic
low
yield
blood
cultur
inadequ
sputum
specimen
infrequ
workup
lung
aspir
bronchoalveolar
lavag
quantif
aetiolog
complic
limit
microbiolog
updat
classif
pneumonia
sever
chang
recommend
firstlin
antibiot
guidanc
reclassifi
cap
requir
treatment
healthcar
facil
three
categori
sever
pneumonia
sever
pneumonia
nonsever
pneumonia
new
approach
design
simplifi
manag
pneumonia
outpati
level
reduc
number
referr
hospitalis
achiev
better
treatment
outcom
sever
pneumonia
defin
cough
difficulti
breath
plu
follow
central
cyanosi
inabl
breastfe
drink
vomit
everyth
convuls
lethargi
unconsci
sever
respiratori
distress
sever
pneumonia
defin
cough
difficulti
breath
one
follow
lower
chestwal
indraw
nasal
flare
grunt
young
infant
sign
sever
pneumonia
especi
month
age
nonsever
pneumonia
defin
cough
difficulti
breath
accompani
tachypnoea
respiratori
rate
breathsminut
infant
age
month
breathsminut
children
age
month
sign
sever
sever
pneumonia
especi
age
month
definit
treatment
failur
includ
develop
sign
sever
sever
pneumonia
persist
rais
respiratori
rate
h
h
area
high
preval
hiv
previou
revis
four
treatment
categori
defin
cap
children
fast
breath
pneumonia
treat
oral
cotrimoxazol
children
chest
indraw
pneumonia
refer
healthcar
facil
treat
inject
penicillinampicillin
result
new
evid
revis
prefer
oral
amoxicillin
oral
cotrimoxazol
treatment
fastbreath
pneumonia
equival
inject
penicillinampicillin
case
chestindraw
pneumonia
sinc
fastbreath
chestindraw
pneumonia
best
treat
amoxicillin
classif
also
revis
new
classif
revis
includ
two
categori
pneumonia
pneumonia
fast
breath
andor
chest
indraw
requir
home
therapi
oral
amoxicillin
sever
pneumonia
pneumonia
gener
danger
sign
requir
referr
inject
antibiot
therapi
recent
publish
intern
clinic
practic
guidelin
also
review
includ
clinic
practic
guidelin
british
nation
formulari
children
bnfc
royal
colleg
paediatr
child
health
rcpch
european
societi
paediatr
infecti
diseas
espid
canadian
paediatr
societi
cp
british
thorac
societi
bt
pediatr
infecti
diseas
societi
pid
summaris
tabl
workup
commun
season
mix
infect
virus
commens
bacteria
sampl
streptococcu
pneumonia
wide
consid
lead
caus
cap
though
proport
vari
region
respons
onethird
radiolog
confirm
pneumonia
children
age
year
pneumonia
commonli
found
asymptomat
nasopharyng
carriag
asymptomat
carriag
state
respons
much
transmiss
within
popul
daycar
centr
haemophilu
influenza
type
b
hib
major
pathogen
though
proport
vari
region
vaccin
coverag
pneumonia
caus
mycoplasma
pneumonia
consid
atyp
bacteri
pneumonia
differ
cours
radiolog
find
treatment
activ
populationbas
surveil
cap
undertaken
hospit
three
american
citi
annual
incid
hospitalis
pneumonia
case
per
children
ci
annual
incid
pneumonia
ci
pneumonia
ci
less
commonli
sever
infect
caus
staphylococcu
aureu
especi
follow
influenza
fungal
infect
pneumocysti
jiroveci
pjp
particularli
import
young
children
aid
furthermor
children
milder
atyp
pathogen
may
recov
without
antibiot
intervent
caus
pathogen
also
vari
age
overal
virus
alon
caus
younger
children
bacteri
caus
found
older
children
commonli
pneumonia
follow
pneumonia
onethird
case
cap
mix
infect
virus
bacteria
virus
commonli
associ
cap
respiratori
syncyti
viru
rsv
parainfluenza
influenza
virus
isol
children
pneumonia
includ
adenoviru
rhinoviru
herp
simplex
viru
enterovirus
human
metapneumoviru
human
bocaviru
coronaviru
overal
virus
account
childhood
cap
frequent
identifi
children
age
year
age
year
empir
therapi
thirdgener
cephalosporin
recommend
children
experi
respiratori
failur
septic
shock
associ
pneumonia
ceftriaxon
cefotaxim
recommend
h
influenza
highlevel
penicillinresist
pneumococcu
rapidli
progress
multilobar
diseas
pneumatocoel
addit
vancomycin
suggest
empir
deescal
ampicillin
subsequ
oral
amoxicillin
vancomycin
recommend
empyema
owe
aureu
pneumonia
detect
blood
respiratori
secret
penicillinsuscept
treatment
either
intraven
ampicillin
penicillin
recommend
follow
oral
therapi
amoxicillin
treatment
pneumonia
c
pneumonia
azithromycin
day
doxycyclin
children
age
year
espid
children
month
ampicillinamoxicillin
gentamicin
recommend
empir
listeria
monocytogen
enterococcu
suspect
ampicillin
altern
cephalosporin
recommend
thirdgener
cephalosporin
avoid
neonat
risk
candidiasi
critic
ill
patient
antistaphylococc
penicillin
clindamycin
vancomycin
recommend
children
age
month
antibiot
antistaphylococc
penicillin
critic
ill
recommend
children
fever
sever
cough
c
trachomati
bordetella
pertussi
suspect
treat
macrolid
children
age
month
year
penicillin
g
aminopenicillin
eg
amoxicillin
recommend
ensur
adequ
cover
pneumonia
atyp
pathogen
age
group
unimmunis
children
treatment
amoxicillin
clavulan
thirdgener
cephalosporin
recommend
secondgener
cephalosporin
may
use
area
low
penicillin
resist
atyp
pathogen
combin
therapi
eg
amoxicillin
clavulan
macrolid
eg
clarithromycin
recommend
well
antistaphylococc
antibiot
critic
ill
idsapid
children
year
age
guidelin
recommend
amoxicillin
amoxicillin
clavulan
presum
bacteri
pneumonia
macrolid
azithromycin
clarithromycin
erythromycin
presum
atyp
pathogen
children
year
age
amoxicillin
amoxicillin
clavulan
macrolid
ad
idsapid
guidelin
recommend
doxycyclin
children
year
clinic
trial
test
effect
short
vs
standard
cours
therapi
children
diagnos
cap
initi
treat
outpati
clinic
urgent
care
facil
emerg
depart
primari
object
compar
composit
overal
outcom
desir
outcom
rank
door
children
cap
age
month
assign
strategi
short
cours
day
vs
standard
cours
day
outpati
therapi
outcom
assess
visit
studi
day
day
studi
commenc
octob
complet
date
march
estim
enrol
patient
malaysian
trial
children
hospitalis
pneumonia
conduct
determin
whether
extend
durat
oral
antibiot
day
better
improv
clinic
outcom
shorter
durat
day
antibiot
patient
experiment
arm
receiv
amoxicillinclavulan
mgkgdose
bd
day
compar
arm
receiv
amoxicillinclavulan
mgkgbd
day
follow
anoth
day
placebo
given
dose
frequenc
studi
began
novemb
aim
enrol
patient
estim
complet
date
decemb
two
clinic
trial
investig
amoxicillin
childhood
pneumonia
conduct
malawi
trial
sponsor
save
children
effect
antibiot
treatment
fastbreath
cap
compar
amoxicillin
therapi
patient
placebo
arm
given
mg
placebo
dispers
tablet
two
divid
dose
base
age
band
mgday
children
month
mgday
children
month
year
mgday
children
year
age
activ
compar
arm
receiv
day
mg
amoxicillin
dispers
tablet
dt
two
divid
dose
base
age
band
mgday
children
month
mg
day
children
month
year
mg
day
children
year
estim
enrol
patient
studi
run
june
septemb
set
anoth
trial
compar
vs
day
treatment
chestindraw
pneumonia
experiment
arm
receiv
day
amoxicillin
day
placebo
compar
arm
receiv
day
amoxicillin
studi
aim
run
march
august
estim
enrol
patient
onearm
safeti
intervent
nigeria
evalu
role
commun
manag
chestindraw
pneumonia
oral
amoxicillin
primari
object
assess
whether
commun
health
worker
safe
appropri
manag
chestindraw
pneumonia
children
age
month
refer
children
danger
sign
systemat
search
systemat
review
metaanalys
antibiot
therapi
cap
publish
english
januari
novemb
undertaken
medlin
cochran
databas
systemat
review
clinicaltrialsgov
search
search
strategi
databas
focus
clinic
trial
control
clinic
trial
review
systemat
review
children
year
search
conduct
novemb
combin
mesh
freetext
term
communityacquir
infect
pneumonia
bacteri
communityacquir
pneumonia
antibiot
antibacteri
agent
pubm
search
relev
guidelin
titl
abstract
full
text
subsequ
data
abstract
screen
independ
follow
consensu
discuss
sever
clinic
trial
antibiot
cap
regist
clintrialsgov
studi
beij
children
hospit
investig
popul
pharmacokinet
cephalosporin
macrolid
antibiot
cap
children
aim
correl
treatment
effect
incid
advers
effect
studi
commenc
august
estim
enrol
children
complet
date
octob
phase
randomis
openlabel
activ
control
multicentr
studi
assess
safeti
efficaci
solithromycin
children
adolesc
cap
conduct
sponsorship
cempra
inc
solithromycin
compar
standard
care
estim
enrol
patient
studi
commenc
march
estim
complet
date
januari
canadian
randomis
control
doubleblind
noninferior
clinic
trial
determin
whether
day
highdos
amoxicillin
lead
compar
rate
earli
clinic
cure
compar
day
highdos
amoxicillin
previous
healthi
children
mild
cap
experiment
arm
patient
given
day
amoxicillin
mgkg
day
three
divid
dose
follow
day
placebo
three
time
day
activ
compar
arm
given
day
amoxicillin
mgkgday
three
divid
dose
follow
altern
formul
day
amoxicillin
mgkgday
three
divid
dose
estim
enrol
studi
patient
commenc
march
complet
date
may
nation
institut
allergi
infecti
diseas
niaid
sponsor
multicentr
randomis
doubleblind
placebocontrol
superior
respect
ceftarolin
fosamil
well
toler
clinic
respons
rate
similar
ceftriaxon
plu
vancomycin
sever
intervent
complementari
antibiot
therapi
manag
cap
success
effort
made
integr
manag
global
vaccin
campaign
integr
global
action
plan
prevent
control
pneumonia
diarrhoea
gappd
aim
address
protect
prevent
treatment
pneumonia
diarrhoea
integr
programm
lowand
middleincom
countri
lmic
sever
identifi
intervent
specif
pneumonia
eg
reduc
household
air
pollut
pneumococc
conjug
vaccin
pcv
hib
pertussi
vaccin
oxygen
therapi
avail
howev
sever
intervent
identifi
complementari
pneumonia
diarrhoea
categoris
protect
breastfeed
promot
support
adequ
complementari
feed
prevent
measl
vaccin
handwash
soap
prevent
hiv
treat
improv
careseek
behaviour
referr
improv
case
manag
commun
health
facil
level
continu
feed
strateg
period
global
allianc
vaccin
immun
gavi
introduc
pcv
countri
includ
bangladesh
cambodia
eritrea
guinea
bissau
lesotho
nepal
solomon
island
uzbekistan
date
estim
gavi
support
million
children
receiv
pcv
howev
coverag
third
dose
vaccin
kemriwellcom
trust
collabor
research
programm
conduct
trial
assess
whether
clinic
outcom
follow
initi
treatment
oral
amoxicillin
sever
pneumonia
effect
current
standard
benzyl
penicillin
openlabel
multicentr
randomis
control
noninferior
trial
treatment
sever
pneumonia
recruit
children
age
month
six
kenyan
hospit
children
randomis
receiv
amoxicillin
benzyl
penicillin
follow
primari
outcom
treatment
failur
h
treatment
fail
patient
amoxicillin
benzyl
penicillin
arm
respect
rd
ci
confirm
noninferior
amoxicillin
benzylpenicillin
indiaclen
multicentr
trial
safeti
efficaci
oral
amoxicillin
sever
aim
includ
approxim
children
age
month
chestindraw
pneumonia
studi
conduct
octob
juli
doubl
blind
efficaci
studi
entitl
retapp
investig
base
aga
khan
univers
karachi
compar
standard
amoxicillin
treatment
placebo
poor
urban
slum
set
south
asia
studi
ran
novemb
juli
enrol
patient
investig
unit
kingdom
initi
multicentr
randomis
doubleblind
placebocontrol
factori
noninferior
trial
amoxicillin
dosag
durat
paediatr
cap
capit
efficaci
safeti
impact
antimicrobi
resist
relat
durat
dosag
amoxicillin
assess
children
age
year
present
emerg
room
paediatr
assess
unit
clinic
diagnosi
cap
decis
made
treat
antibiot
particip
randomis
four
treatment
group
shorter
cours
lower
dose
day
mgkgday
longer
cours
lower
dose
day
mgkgday
shorter
cours
higher
dose
day
mgkgday
longer
cours
higher
dose
day
mgkgday
expect
recruit
year
march
may
ceftarolin
fosamil
broadspectrum
cephalosporin
antibiot
activ
mani
bacteria
includ
pneumonia
penicillinnonsuscept
multidrugresist
strain
aureu
includ
methicillinresist
aureu
phase
studi
paediatr
patient
hospitalis
cap
receiv
either
intraven
ceftarolin
fosamil
ceftriaxon
randomis
activecontrol
observerblind
clinic
trial
effect
ceftarolin
fosamil
similar
ceftriaxon
high
clinic
cure
rate
test
cure
modifi
intentiontotreat
popul
respect
three
document
aureu
infect
success
treat
ceftarolin
group
includ
one
caus
methicillinresist
aureu
phase
studi
safeti
effect
ceftarolin
fosamil
children
evalu
multicentr
randomis
observerblind
activecontrol
trial
ceftarolin
fosamil
compar
intraven
ceftriaxon
plu
vancomycin
patient
age
month
year
complic
cap
clinic
respons
rate
modifi
intentiontotreat
popul
patient
ceftarolin
fosamil
group
compar
group
clinic
stabil
studi
day
whodefin
severeseverenonsever
cap
includ
studi
particip
includ
children
age
month
cap
twentytwo
studi
enrol
children
includ
metaanalys
combin
penicillinampicillin
gentamicin
effect
sever
pneumonia
oral
amoxicillin
effect
parenter
antibiot
oral
amoxicillin
also
found
effect
nonsever
pneumonia
review
found
short
cours
antibiot
benefici
cours
nonsever
pneumonia
children
age
month
systemat
review
expert
survey
review
identifi
sever
candid
predictor
oral
antibiot
failur
current
use
childhood
pneumonia
referr
algorithm
includ
excess
agespecif
respiratori
rate
young
age
abnorm
oxygen
satur
moder
malnutrit
children
age
month
resourcelimit
set
whodefin
nonsever
pneumonia
fast
breath
age
andor
lower
chestwal
indraw
without
danger
sign
nine
studi
met
inclus
criteria
oral
antibiot
failur
rate
rang
six
studi
found
excess
ageadjust
respiratori
rate
defin
either
whodefin
fast
breath
age
breathsmin
faster
normal
ageadjust
threshold
breathsmin
age
month
breathsmin
age
month
four
studi
report
young
age
predict
failur
oral
antibiot
question
pneumonia
spectrum
specif
macrolid
use
cap
commonli
encount
paediatr
practic
metaanalysi
children
communityacquir
lower
respiratori
tract
infect
treat
specif
pneumonia
undertaken
sixteen
articl
detail
studi
includ
sever
lowqual
studi
found
reduct
fever
durat
clinic
impact
effect
unclear
metaanalysi
five
randomis
control
trial
show
pool
risk
differ
ci
favour
treatment
macrolid
tetracyclin
quinolon
class
antibiot
statist
signific
overal
author
consid
insuffici
evid
support
conclus
efficaci
macrolid
pneumonia
cap
children
futur
studi
highlight
potenti
confound
mix
infect
time
intervent
rel
symptom
onset
test
modal
includ
combin
serolog
polymeras
chain
reaction
assay
high
preval
cap
children
mean
clinician
public
health
expert
face
ongo
challeng
prescrib
antibiot
children
challeng
frame
apprais
evid
guid
antibiot
choic
pneumonia
home
hospit
compar
openlabel
multicentr
prospect
twoarm
randomis
clinic
trial
children
age
month
sever
pneumonia
aim
determin
differ
treatment
failur
cours
oral
amoxicillin
first
h
hospit
sent
home
treatment
enrol
total
children
enrol
randomis
home
n
hospit
group
n
overal
treatment
failur
rate
per
protocol
analysi
intentiontotreat
analysi
treatment
significantli
like
fail
hospit
group
home
group
death
rate
day
differ
significantli
rd
ci
median
total
treatment
cost
inr
home
group
inr
hospit
group
p
failur
rate
day
treatment
random
subsampl
homebas
treatment
oral
amoxicillin
equival
hospit
treatment
first
h
children
chestindraw
pneumonia
less
expens
cochran
review
examin
antibiot
cap
children
made
recommend
countri
high
case
fataliti
rate
owe
pneumonia
children
without
underli
morbid
pointofcar
test
identifi
aetiolog
agent
pneumonia
avail
twentynin
trial
compar
multipl
antibiot
children
enrol
includ
nonsever
cap
ambulatori
set
amoxicillin
compar
cotrimoxazol
similar
failur
rate
ci
cure
rate
ci
children
sever
pneumonia
without
hypoxaemia
oral
antibiot
amoxicillincotrimoxazol
compar
inject
penicillin
similar
failur
rate
ci
hospitalis
rate
ci
relaps
rate
ci
sever
cap
death
rate
higher
children
receiv
chloramphenicol
receiv
penicillin
ampicillin
plu
gentamicin
ci
base
find
amoxicillin
recommend
cotrimoxazol
patient
cap
ambulatori
set
amoxicillin
clavulan
cefpodoxim
altern
secondlin
drug
oral
amoxicillin
recommend
children
ambulatori
set
sever
pneumonia
without
hypoxaemia
children
hospitalis
sever
sever
cap
penicillinampicillin
plu
gentamicin
superior
chloramphenicol
altern
drug
patient
amoxicillin
clavulan
cefuroxim
metaanalysi
trial
lmic
undertaken
determin
suitabl
antibiot
therapi
treat
pneumonia
sever
sever
nonsever
examin
type
drug
durat
ill
combin
therapi
randomis
control
trial
quasirct
assess
rout
dose
combin
durat
antibiot
manag
pneumococc
isol
report
european
antimicrobi
resist
surveil
network
earsnet
larg
major
isol
serogroup
suscept
penicillin
macrolid
serogroup
isol
decreas
suscept
penicillin
andor
macrolid
countri
report
earsnet
serogroup
preval
account
isol
respect
follow
serogroup
serogroup
among
commonli
report
serogroup
dual
nonsuscept
penicillin
macrolid
mainli
observ
serogroup
order
decreas
percentag
singl
nonsuscept
penicillin
common
serogroup
singl
nonsuscept
macrolid
common
serogroup
efficaci
pneumococc
conjug
vaccin
assess
compar
rate
invas
pneumococc
diseas
children
introduct
unit
state
timeseri
model
use
compar
report
incid
invas
pneumococc
diseas
ipd
would
expect
replac
author
determin
overal
incid
ipd
declin
ci
ipd
caus
minu
serotyp
declin
ci
estim
case
ipd
death
avert
first
year
introduct
effect
vaccin
assess
match
casecontrol
studi
total
case
invas
pneumococc
diseas
children
age
month
identifi
activ
surveil
site
control
identifi
birth
registri
match
case
age
post
code
serotyp
case
includ
commonli
identifi
serotyp
vaccin
effect
serotyp
ci
invas
pneumococc
isol
recov
children
age
year
activ
bacteri
core
surveil
analys
n
n
implement
pneumococc
conjug
vaccin
pcrelectrospray
ionis
mass
spectrometri
whole
genom
sequenc
wg
analysi
use
antibiot
dose
play
import
role
advers
event
turn
complianc
treatment
antibioticassoci
diarrhoea
aad
wellrecognis
advers
reaction
amoxicillin
review
report
rate
aad
follow
oral
penicillin
treatment
paediatr
clinic
trial
quantifi
evid
elucid
dearth
strong
evid
field
paediatr
patient
aad
amoxicillin
pool
rate
six
studi
rang
howev
demonstr
correl
dose
amoxicillin
rate
aad
importantli
associ
age
diarrhoea
relat
oral
penicillin
younger
children
age
month
year
experienc
higher
rate
add
children
age
older
year
import
consid
aad
precis
mechan
robust
evid
dosetoaad
rate
respons
remain
demonstr
work
requir
assess
role
dose
durat
aad
rate
includ
diarrhoea
use
standardis
definit
outcom
measur
randomis
control
trial
issu
surveil
global
difficulti
surveil
antimicrobi
resist
amr
owe
limit
laboratori
capac
harmonis
diagnost
procedur
lack
surveil
network
map
amr
underresourc
countri
requir
focu
specimen
ship
condit
data
standardis
absenc
contamin
adequ
diagnost
consid
avail
data
pneumonia
resourcelimit
set
extent
outpati
penicillin
use
correl
degre
resist
invas
isol
surveil
studi
hospitalis
patient
asian
countri
highlevel
penicillin
resist
much
lower
level
resist
erythromycin
multidrug
resist
south
africa
isol
pneumonia
identifi
resist
three
typic
antibiot
howev
import
note
amr
data
often
come
hospit
attend
wealthi
patient
introduc
bia
furthermor
import
surveil
pneumococc
pathogen
integr
effect
public
health
measur
conjug
vaccin
effect
vaccin
serotyp
select
widespread
use
pneumococc
vaccin
alter
landscap
resist
infect
paediatr
carriag
reduc
classic
resist
serotyp
cover
current
avail
multival
pcv
vaccin
serogroup
common
outcom
similar
better
tradit
longer
durat
identifi
minimum
intraven
antibiot
durat
less
one
day
sever
complic
cap
initi
intraven
treatment
recommend
base
expert
opinion
criterion
switch
oral
antibiot
clinic
improv
minimum
total
antibiot
durat
day
mild
cap
fewer
equal
day
moder
sever
uncompl
cap
oral
antibiot
deem
accept
children
requir
hospit
admiss
cochran
review
examin
randomis
control
trial
evalu
efficaci
shortcours
day
vs
longcours
day
intraven
antibiot
therapi
sever
pneumonia
children
age
month
children
debilit
diseas
hiv
infect
sever
pneumonia
nosocomi
pneumonia
exclud
total
studi
identifi
none
fulfil
inclus
criteria
conclus
data
present
demonstr
evid
recommend
amend
current
revis
classif
treatment
childhood
pneumonia
health
facil
either
term
drug
choic
dose
durat
recent
systemat
review
support
recommend
new
trial
evid
counter
view
review
focuss
recent
aetiolog
studi
data
advanc
molecular
diagnost
eg
pneumococc
dna
load
predict
viral
bacteri
respiratori
infect
number
cap
amoxicillin
trial
underway
compar
vari
dose
durat
regimen
although
limit
harmonis
yet
studi
design
trial
may
relev
lmic
set
trial
yet
includ
amr
outcom
make
assess
optim
treatment
recommend
popul
level
amr
perspect
current
possibl
major
need
trial
determin
overal
optim
durat
treatment
hospitalis
children
sever
sever
pneumonia
optim
choic
antibiot
oral
stepdown
regimen
also
unclear
specif
amoxicillin
compar
agent
treat
staphylococc
infect
amoxicillin
clavulan
number
emerg
theme
identifi
optim
dose
recommend
amoxicillin
remain
unclear
concern
recent
adult
pharmacokinet
data
twicedaili
dose
set
high
pneumococc
resist
mg
amoxicillin
dispers
tablet
cover
paediatr
dose
requir
unclear
whether
amoxicillin
broaderspectrum
antibiot
commonli
use
treat
cap
differ
region
difficult
assess
uptak
implement
cap
guidanc
remain
global
relev
headtohead
pragmat
trial
directli
compar
effect
amoxicillin
oral
cephalosporin
macrolid
ambulatori
set
optim
antibiot
manag
hospitalis
children
sever
sever
pneumonia
well
sever
pneumonia
older
hospitalis
children
remain
unclear
identifi
serotyp
resist
featur
genotyp
pilu
type
target
major
genotyp
decreas
antimicrobi
resist
primarili
owe
remov
complex
strain
complex
contribut
remain
resist
signific
emerg
nonvaccin
clonal
complex
evid
remov
vaccin
serotyp
strain
posit
one
pilu
type
decreas
year
rel
decreas
combin
betalactam
suscept
phenotyp
correl
consist
transpeptidas
region
sequenc
combin
three
major
penicillinbind
protein
pbp
determin
wg
analysi
major
resist
featur
predict
dna
signatur
wg
analysi
multilocu
sequenc
data
combin
pbp
combin
identifi
progeni
serotyp
donor
recipi
strain
serotyp
switch
event
decreas
frequenc
serotyp
clone
concurr
decreas
frequenc
strain
subset
resist
andor
adher
featur
conduc
success
carriag
effect
vaccin
diseas
sever
link
diseas
sever
serotyp
adult
evalu
serotyp
cover
conjug
pneumococc
vaccin
serotyp
compar
nonvaccin
serotyp
differ
seen
diseas
sever
associ
mortal
among
patient
infect
pcv
serotyp
compar
patient
infect
nonvaccin
serotyp
invas
pneumococc
diseas
older
age
underli
chronic
diseas
immunosuppress
sever
diseas
significantli
associ
mortal
associ
found
nosocomi
infect
invas
serotyp
mortal
risk
factor
mening
suppur
lung
complic
preexist
lung
diseas
significantli
associ
diseas
sever
independ
infect
serotyp
overal
host
factor
import
isol
serotyp
determin
sever
outcom
invas
pneumococc
diseas
adult
studi
avail
inform
durat
intraven
antibiot
children
safe
appropri
switch
oral
antibiot
shorter
antibiot
cours
potenti
affect
antimicrobi
resist
durat
time
switch
antibiot
administr
intraven
oral
paediatr
infecti
diseas
systemat
review
recommend
develop
minimum
intraven
total
antibiot
durat
requir
achiev
